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Abstract
Purpose To find out what is known from literature about Long COVID until January 30, 2021.
Methods We undertook a four-step search with no language restriction. A preliminary search was made to identify the
keywords. A search strategy of all electronic databases resulted in 66 eligible studies. A forward and backward search of the
references and citations resulted in additional 54 publications. Non-English language articles were translated using Google
Translate. We conducted our scoping review based on the PRISMA-ScR Checklist.
Results Of 120 papers, we found only one randomized clinical trial. Of the 67 original studies, 22 were cohort, and 28 were
cross-sectional studies. Of the total 120 publications, 49.1% focused on signs and symptoms, 23.3% on management, and
10.8% on pathophysiology. Ten publications focused on imaging studies. The results are also presented extensively in a narrative synthesis in separated sections (nomenclature, diagnosis, pathophysiology, risk factors, signs/symptoms, management).
Conclusions The controversies in its definition have impaired proper recognition and management. The predominant symptoms were: fatigue, breathlessness, arthralgia, sleep difficulties, and chest pain. Recent reports also point to the risk of longterm sequela with cutaneous, respiratory, cardiovascular, musculoskeletal, mental health, neurologic, and renal involvement
in those who survive the acute phase of the illness.
Keywords COVID-19 · Long COVID-19 · Long haulers COVID · Post COVID-19 Syndrome · Post-acute COVID-19 ·
Corona virus · SARS-Cov-2 · Novel Corona Virus 2019 · Post-acute SARS-CoV-2 · PASC post-acute sequela SARSCOV-2
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Introduction
Descriptions of long-lasting symptoms after influenza-like
illnesses can be traced back to 1892 when Josephine Butler, a women’s right campaigner, wrote to her son complaining of unresolved fatigue after being infected with the
Russian Influenza. In 1895, politicians in the United Kingdom, including the prime minister, who were infected with
the Russian Influenza reflected in their periodicals and
diaries about the long-lasting fatigue and insomnia [1].
More recent viral infections such as Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV-1) and the Middle East Respiratory Syndrome Coronavirus (MERS-CoV)
have also been associated with unabating post-acute phase
lingering symptoms. In a systematic review of prolonged
symptoms of SARS-CoV-1 and MERS-CoV by Ahmed
et al., approximately one-third of the patients suffered
from prolonged anxiety, depression, and post-traumatic
stress disorder (PTSD) up to 6 months after complete
recovery from the acute illness [2]. Moreover, they found
that 11–45% of the patients had diminished DLCO (diffusing capacity of the lungs for carbon monoxide) at one-year
follow-up [2].
SARS-CoV-1 survivors have been reported to suffer from long-term pulmonary complications, such as
impaired exercise capacity, reduced DLCO, and interstitial lung abnormalities [3]. Additionally, in long-term
follow-up of 121 SARS-CoV-1 survivors, cardiovascular
complications were quite common: hypotension (50.4%),
tachycardia (71.9%), bradycardia (14.9%), and cardiomegaly (10.7%) [4]. Other long-term abnormalities associated with SARS-CoV-1 were persistent hyperlipidemia
and derangements in glucose hemostasis [5]. While acute
renal impairment [6], acute gastrointestinal effects [7],
acute viral hepatitis [8], and acute diabetes mellitus from
the binding of the virus to its receptors on pancreatic islets
cells [9] were reported, the long term consequences were
not mentioned. Moreover, hematologic abnormalities, such
as lymphopenia, leukopenia, thrombocytopenia, prolonged
activated partial thromboplastin time (aPTT), coagulopathy (elevated D-dimer) and disseminated intravascular
coagulation (DIC), and a pro-thrombotic state at microand macro- vasculature involving both veins and arteries
with thromboembolic complications have been observed
in the acute phase of these viral infections with potential
long term consequences [10, 11]. In regard to psychosocial
manifestations, a considerable number of SARS-CoV-1
patients suffered from chronic widespread musculoskeletal
pain, fatigue, psychological stress, and disturbed sleep,
hindering their return to productive work for up to 2 years
after acute illness [12, 13]. In their 1-year follow-up of the
survivors, Tansey et al., reported that more than half of
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the patients still experienced fatigue and sleep disturbance
[14]. The subject of post-acute COVID-19 was recently
reviewed by Amenta et al. [15].
Similarly, in a study of recovered patients from MERSCoV, abnormal chest radiographs with ground-glass opacities and pleural thickening, indicative of pulmonary fibrosis,
were still present at a median of 43 days after discharge from
the hospital [16]. Although both SARS-CoV-1 and MERSCoV have been associated with neurologic sequela, the latter
is believed to be more neuro-invasive, causing complications
such as paralysis, ischemic stroke, Guillain–Barre syndrome,
and neuropathy [10, 17].
Despite considerable concerns about the long-lasting
symptoms of COVID-19, our collective understanding and
approach to its management are still in their infancy. This
scoping review elaborates upon the up-to-date knowledge
regarding this so-called “Long COVID” and attempts to shed
light on future needs in this area. Due to the diversity and
yet relative paucity of evidence, conducting a conventional
systematic review would be less beneficial; thus, we conducted a systematic scoping study on this topic to highlight
the currently available literature and to identify gaps in our
knowledge. We hope our effort would reveal areas that need
immediate attention and guide future research efforts.
Our focus here is to synthesize what is known from literature about the persistent COVID-19, its signs and symptoms, its pathophysiology, and the current management recommendations. We also wish to highlight the gaps in our
knowledge regarding ‘long COVID’ syndrome.

Method
Since the review question is comprehensive, we found the
systematic scoping review as the most suitable methodology
to answer the question. To achieve clarity and transparency
and to avoid poor reporting, we used Preferred Reporting
Items for Systematic reviews and Meta-Analyses extension
for Scoping Reviews (PRISMA-ScR) [18].
Review question
What is known from literature about the long COVID-19,
its nomenclature, diagnosis, risk factors, signs/symptoms,
pathophysiology, and the currently recommended management, and what are the gaps in this issue?
Inclusion criteria
• Those related to long COVID, post-acute COVID, and

long haulers of COVID-19

• Those related to nomenclature, diagnosis criteria, patho-

physiology, signs and symptoms, and managements
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• All types of reports were included: original studies

(cohort, RCT, case–control, case-report, case series, and
qualitative), reviews and editorials, viewpoints, guidelines, letter to editors and commentaries.
• The articles should have been published in a peerreviewed journal or be an organizational report
• No language restriction was considered.
Exclusion criteria
•
•
•
•

Those irrelevant to COVID-19
Those related to acute COVID-19
Preprints
Unavailable full texts

Search strategy
We followed a four-step search strategy. First, on January
20, 2021 a limited preliminary search was done in multiple
databases such as Google Scholar and PubMed for identifying the appropriate keywords. Next, on January 30, 2021 we
adopted a search strategy including electronic databases of
the following sources: Cochrane Library, PsycINFO, PubMed, Embase, Scopus, and the Web of Sciences. The results
were reviewed using Endnote 20. After duplicate publications were removed, two authors separately checked the titles
and abstracts and removed irrelevant studies according to
the inclusion and exclusion criteria. Discrepancies about
the inclusion/exclusion of any paper were resolved through
discussion. Third, the two authors separately checked the
included papers’ reference lists for identifying more relevant
studies. In the fourth step, we glimpsed at google scholar
for articles’ citing and current publications, maximizing
our efforts to collect all relevant studies. Again, discrepancies were discussed for final approval in the third and fourth
steps. We used the following keywords for our literature
search: "long COVID" or "long haulers," or "post-acute
COVID" or "chronic COVID syndrome" or "late sequela
COVID" or "persistent COVID”. Table 1 shows our search
strategy on all databases. As we had chosen no language
restriction, we used Google to translate non-English papers
and checked their eligibility.
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Data extraction and synthesis
The following items were extracted from included papers:
first author, country of the first author (also region and
income level of the country), date of publication, date of
submission, type of study (also the methodology in case of
an original study), study category (diagnosis, nomenclature,
pathophysiology, risk factors, signs/symptoms, or management), main topics in the categories (rehabilitation, pharmacologic options, thromboembolism, etc.), and the number
of patients studied in the original investigations, their countries’ population and income level.
Moreover, for the original investigations, we extracted the
following data from the articles: methodological approach,
number of patients, the country and the geographic region
where patients were investigated, based on World Bank
report (2020–2021 fiscal year) [19]. A data extraction form
was designed in Excel, and 3 independent authors extracted
the data. Discrepancies were resolved through discussion. In
the discussion section, we have synthesized the core themes
of the study. The discussion section is divided into 6 categories where we present perspectives around nomenclature,
diagnosis, pathophysiology, signs and symptoms, risk factors, and management of long COVID. Finally, we address
the gaps and propose suggestions in the conclusion section.

Results
We retrieved 290 publications from our search (Fig. 1). After
removing duplicates, publications were screened for the relevance of the title and abstract, resulting in the exclusion of
33 more publications. Then, 86 publications were evaluated
for full-text eligibility. Of those, 20 articles were excluded
(14 articles were not related to the Long COVID subject,
and 6 were not available in full text). We were left with 66
articles for data synthesis. We then performed forward and
backward screening of these papers’ references and citations to identify as many relevant studies as possible. We
found 54 additional relevant publications, that made a total
of 120 publications as the basis for our analysis (see Online
appendix 1).

Table 1  Keywords and search strategy
Database

Search strategy and keywords

Pubmed

Title and abstract

Embase
Web of sciences
Scopus
Psycinfo
Cochrane Library

Title, abstract, and keywords

"Long COVID" or "long haulers" or "post-acute COVID" or "late sequela COVID" or "persistent COVID" or "chronic COVID syndrome"
"Long COVID" or "long haulers" or "post-acute COVID" or "late sequela COVID" or "persistent COVID" or "chronic COVID syndrome"
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Fig. 1  PRISMA flow chart, the process of study selection. WOS Web of Science

Types of included papers
The first published papers date back to March 2020. The
number of publications significantly increased over time.
The distribution of the publications, based on the type of
publication, is shown in Fig. 2. Of the 120 publications
(Table 2), 67 (55.9%) presented original data as follows:
43 (35.9%) were original articles/papers [20–62]. Fifteen
(12.5%) publications were short articles with original
data, as follows: 7 brief communications/reports [63–69]
(5 cohort and 1 cross-sectional studies, and 1 case series),
1 commentary [70] (cross-sectional study), 6 letters to
editors [71–76] (4 cross-sectional and 1 cohort studies,
and 1 case series), and 1 short communication [77]. Fiftyfour (45%) articles did not present original data. Among
them were 33 (27.5%) short articles (shown in Fig. 2
as “non-original short communications”) as follows: 5
commentaries [78–82], 3 letters to the editors [83–85],
1 short communication [86], 1 “piece of mind” [87], 4
“news” [88–91], 1 perspective [1], 15 editorials [92–106],
1 special article [107], and 2 viewpoints [108, 109]. The
other articles in this category were: 9 case reports/case
series [110–118], 10 narrative reviews [10, 15, 119–126],
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1 systematic review on the respiratory system [127], 4
guideline papers, 3 clinical updates, 1 “report”, and 1
consensus statement [128]. There was only 1 systematic
review that elaborated on the pulmonary aftermaths of
Long COVID [127]. There were 3 qualitative studies [26,
47, 57], only in 2 of them [26, 57], the study populations
were well described. That was of significant concern since
in qualitative studies the populations’ cultural and contextual aspects should be vividly mentioned.
We found only one randomized clinical trial in our
search [60]. Of all documents, 67 (55.9%) were studies
with original data. Of those with original data, cross-sectional and cohort studies were the most common methodologies comprising 28 and 22 manuscripts, respectively.
We found 3 qualitative studies; 2 from the UK and another
1 that did not explicitly mention the population region.
More details are shown in Fig. 3. In our classification, we
distinguished papers with original information from those
that did not present empiric information. For instance, we
divided the letter to the editors into two separate groups,
those that contained original data and mentioned specific
methodology, and those that did not do so.
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Fig. 2  Distribution of included
papers based on types of publication

Table 2  The distribution of papers, based on types of publication
Type of article

Total number

Original articles [20–62]
Brief communications/reports [63–69, 77, 86]
Letter to editor [71–76, 83–85]
Commentary [70, 78–82]
Editorial [92–106]
Case series [110, 111, 113]
Case reports [112, 114–118]
Guideline [129, 132, 133, 135]
Narrative Review [10, 15, 119–126]
Systematic review [127]
News [88–91]
Viewpoint [108, 109]
Perspective [1]
Piece of mind [87]
Clinical update [136]
Consensus statement [128]
Reports [130]
Special article [107]
Practice [131, 134]

43
9
9
6
15
3
6
4
10
1
4
2
1
1
1
1
1
1
2

Categories of included papers
As shown in Fig. 4, 13 (10.8%) articles, mainly editorials
and commentaries, discussed a mixture of the following categories: nomenclature, signs/symptoms, pathophysiology,
management, diagnosis, and risk factors. Fifty-nine (49.2%)
articles presented signs and symptoms of Long COVID.
Twenty-three (19.2%) articles reported on the generalized

signs/symptoms (21 adults, 2 pediatrics), and the remaining 36 (30%) articles focused on specific organs/systems (9
focused on thromboembolism [29, 30, 36, 50, 66, 69, 114,
117, 118], 8 respiratory [23, 27, 37, 41, 44, 67, 75, 127], 4
neurology [46, 61, 102, 116], 2 musculoskeletal [53, 72], 5
cardiovascular [39, 49, 54, 112, 120], 3 mental health [21,
58, 108], 2 Multisystem Inflammatory Syndrome [MIS] [43,
113] (one about pediatrics MIS [43] and one on adults MIS
[113]), 1 skin manifestations [70], 2 were exclusively about
post-acute infectious fatigue [33, 122].
Thirteen (10.8%) articles evaluated the pathophysiology
of Long COVID, including 8 neurologic [20, 32, 40, 73, 93,
104, 109, 126], 2 cardiovascular [77, 92], 1 fatigue [124],
and 1 MIS in pediatric [121]. One paper was concerning
the pathophysiology of multiple systems called in Fig. 4 by
“multi-system” [31].
Twenty-eight (23.3%) articles were regarding management options: 13 rehabilitation care [22, 28, 45, 59, 60, 71,
94, 115, 119, 123, 129–131], 5 general care [26, 47, 57,
105, 132], 1 designed and validated a psychometric tool for
assessing mental health consequences of Long COVID [42],
and 1 was about “how to return back to the pre-morbidity
activity level” [63], and 8 articles were on more comprehensive “multidisciplinary-care” of long COVID patients [84,
90, 98, 107, 128, 133–135].
Among the articles that are included in our report is an
editorial from The Lancet that discusses historically the persistent symptoms after Russian influenza up to the current
COVID-19 [1]. We also included a letter that proposed criteria for the definition of Long COVID [82].
There were several articles concerning the imaging features of Long COVID; but only 10 had focused explicitly
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Fig. 3  Distribution of included
papers based on their methodology. RCTRandomized Clinical
Trial

Thromboembolism, 9

Respiratory, 8

Back to usual activity, 1

Pediatric Long COVID (MIS), 1
Psychometric tool, 1
Pediatric Long COVID (general), 2

Risk factor, 1 (0.8%)
Mixed, 13 (10.8%)

Neurology, 4
Musculoskeletal, 2

General care, 5

Diagnosis, 1 (0.8%)
History of medicine, 1 (0.8%)

Rehabilitation care, 13

Signs and Symptoms, 59 (49.2%)
Management, 28 (23.4%)

Multi-system, 21

Nomenclature, 4 (3.4%)
Multi-care, 8

Pathophysiology, 13 (10.8%)

Cardiovascular, 2

MIS in adult, 1

General (Fatigue), 1

Mental health, 3

Multi-system, 1
General (Fatigue), 2

Neurology, 8
cutanous, 1

Cardiovascular, 5

Pediatric Long COVID (MIS), 1

Fig. 4  Categories and main topics of included papers; Inner doughnut illustrates the categorization of documents, and the outer doughnut illustrates the main topics of each category. MIS Multisystem Inflammatory Response
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and precisely on the radiologic features (3 MRI of the brain
and olfactory nerves [20, 32, 40], 5 cardiovascular system
including MRI, PET/CT and Echocardiography [39, 49, 54,
63, 77], 2 lung CT scan [44, 75]).
There were several articles that discussed the risk factors
and predictors of developing Long COVID. However, only
1 article focused on the risk factors for developing mental health problems post-COVID [125]. Also, 1 article was
about developing a psychometric tool to assess the mental
health consequences of long COVID [42].

Date of submission and publication
There has been an increasing interest in literature on Long
COVID. Our search was limited to the end of Jan 2021
(search in databases) and early February 2021 (backward
and forward search). In our forward and backward search,
we found three articles with a “first-online” in February
2021. Our analysis tried to evaluate the submission date,
but we could not find the submission date for 53 articles. We
report both dates of submission and publication to be more
informative (Fig. 5).

Countries and regions
To overview the global spread of the works done on long
COVID, we chose the first authors’ countries for the authors’
representativeness. For each country, geographical region
and level of income were included in our analysis as well.
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In regard to the countries and geographic regions of the
first authors, 74 (62%) authors were from 4 countries: 31
from UK, 19 from USA, 14 from Italy, and 10 from China.
In regard to geographic regions, 61 (58%) authors were from
Europe and Central Asia, 21 (17.6%) from North America,
12 from East Asia and Pacific, 6 from South Asia, 5 from the
Middle East and North Africa, 2 from Sub-Saharan Africa,
and 1 from Latin America and the Caribbean. According to
the World Bank categorization of countries in 2020–2021
fiscal year, we categorized these regions to High, Uppermiddle, lower-middle, and low-income countries [19].
Ninety-three (78.2%) first authors were from high-income
countries, and only one author was from a low-income
country.
There were 7 original studies on rehabilitation as the cornerstone management of Long COVID: 3 from Italy [28, 45,
71], 2 from China [59, 60], 1 from Austria [22], and 1 from
Malawi [115].

Number of patients
As shown in Table 3, we report the number of patients based
on the methodology of studies, level of income, and the
regions of the investigated populations.

Language of the papers
Also, as the study was done without any language restriction, we screened title/abstract as well as the main text of

Fig. 5  Number of articles
according to dates of submission and publication
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Table 3  Number of articles and number of patients studied, based on
study methodology, country income, and geographic region
Number
Number of patients
of studies
Methodology
Case report
Case series
Case–control
Cohort
Cross-sectional
Longitudinal observational
Qualitative
RCT
Level of income
High
Upper middle
Lower middle
Low
Region
Europe and Central Asia
North America
East Asia and Pacific
The Middle East and North Africa
South Asia
Sub-Saharan Africa
Multinational

6
5
1
22
27
1
3
1

1 for each
5, 5, 7, 16, 145
157
10–1877*
8–6049*
51
24, 43, 114
72

46
14
1
2

1–2286*
1–6049*
1
1 for each

40
9
9
2
1
2
3

1–2286*
1–570*
26–6049*
52, 1529
1
1 for each
16, 234, 2113

*Range

non-English papers. Finally, we included one non-English
paper in the Spanish language [137].

Discussion
Our study retrieved 120 papers based on inclusion and exclusion criteria. Hereby, we present them in five separate sections: “debates on nomenclature”, “pathophysiology”, “sign
and symptoms”, “management”, and “concluding comments
and suggestions”.

Debates on nomenclature
A standardized nomenclature is a gateway to adequate service provision and proper management of an illness. Thus,
the lack of a standardized universally accepted definition and
nomenclature for this disorder makes its appropriate diagnosis and management quite challenging. Many healthcare
professionals and researchers are worried about attributing
all symptoms to a single diagnosis. This could lead to a
binary or even a quadripartite view that the symptoms such
patients experience could be the result of up to four different
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syndromes (Permanent damage to vital organs; Post-intensive-care syndrome; Post-viral fatigue syndrome; and continued COVID-19 syndrome) [89]. This confusion has led
to many patients with ongoing symptoms being ignored or
not taken seriously. The hashtag "#Long COVID" has been
frequently used in social media [86]. However, we found in
our search that it lacks a universal definition. For example,
National Institute for Health and Care Excellence (NICE)
defined the "Long COVID" as "signs and symptoms that
develop during/after the COVID-19 infection persisting for
more than 4 weeks and could not be explained by any other
diagnosis". In this categorization, the Long COVID consists of two categories, "Ongoing symptomatic COVID-19″,
which indicates the symptoms lasting for 4–12 weeks; and
"Post-COVID-19 syndrome", which means symptom persistence beyond 12 weeks [134].
Sivan et al., concur with our viewpoint that the definition
presented by NICE is based on an obscure "by exclusion"
diagnostic criteria. And that this categorization is not inclusive enough for all the post-acute complications of SARSCOV-2 under a single unified definition. It is suggested that
the definition be changed to "continuing signs/symptoms
beyond 4 weeks that can be attributed to COVID-19 infection" [103].
Baig has suggested using the term "Chronic COVID
syndrome (CCS)" as opposed to “Long-COVID” or “LongHaulers”. He also presented an organ-based staging of the
illness to prioritize immediate care needs [78]. However,
in a publication in the journal Nature, Marshall proposed
the term "Coronavirus Long-Haulers" for those suffering
from this condition [88]. Moreover, Greenhalgh et al., has
proposed the term "post-infectious COVID-19" for those
who continued with symptoms beyond 3 weeks after the
onset of the disease. In this definition, the pre-requisition of
a definite positive test for diagnosis was not considered since
many patients are not tested, and false negatives are common [134]. In agreement with prior classification, Amenta
et al., suggested that for COVID-19 patients hospitalized
for 3 weeks, the onset of the post-infectious state could be
delayed to the time of discharge from inpatient acute care
services [15]. More recently, Anthony Fauci, MD director
of the National Institute of Allergy and Infectious Diseases
(NIAID), suggested the name “post-acute sequelae of SARSCoV-2 infection” (PASC) [138].
Reaching an agreement on a definite terminology is vital.
Using terms such as "post", "chronic", or "syndrome" carries
assumptions about the underlying pathophysiology, which is
unclear yet [97]. In our third and fourth phase of the search
(looking at references and citations) we found almost a similar number of publications as our initial search (66 vs. 54
publications) of the databases. The authors believe that the
lack of a standardized nomenclature resulted in poor homogeneity of the titles. This suggests that the WHO and other
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related organizations should make relevant unified terms to
homogenize the literature. Besides, we suggest that other
investigators use similar multi-step search strategies not to
miss any relevant studies.

Diagnosis
In addition to debates on the nomenclature, there is also
uncertainty on diagnostic criteria. There is the scarcity of
discussion and proposals for such diagnostic criteria. We
found only 1 article focused on the diagnostic criteria.
Raveendran’s proposed criteria for Long COVID-19 consisted of 3 sectors: essential criteria, clinical criteria, and
duration criteria [82]. Symptomatic and asymptomatic cases
(during the acute phase) were separated, and each group
based on RT-PCR, serologic testing, characteristic radiologic findings, and being in a high- or low- prevalence community was categorized into four subgroups: confirmed,
probable, possible, or doubtful. In regard to duration criteria
for such diagnosis the author proposed: beyond 2 weeks for
mild disease, beyond 4 weeks for moderate to severe illness,
and beyond 6 weeks for the critically ill in the acute phase.
For those with asymptomatic acute phase: appearance of
symptoms 1 week after antibody positivity or 2 weeks after
having a positive RT-PCR or positive radiologic finding or
contact with a suspected or positive COVID-19 case. Doubtful cases in the acute phase would fulfill the duration criteria
of long COVID once they develop symptoms [26].
A few other reports have merely suggested a durationcriteria for long COVID, as persistence of symptoms beyond
3 weeks of the disease onset. The above-mentioned article
is the only one that proposed a full-spectrum diagnosticcriteria. This lack of well-defined criteria to define Long
COVID-19 emphasizes the need for international-healthorganizations, such as, WHO to address this issue.

Pathophysiology
SARS-COV-2 virus invades many tissues and has a multiorgan and multisystem impact [130]. It is not unexpected,
given that the Angiotensin-Converting Enzyme 2 (ACE2)
receptor is expressed in many tissues [95]. Regarding the
pathophysiology and underlying mechanism(s) involved
in Long COVID, Baig suggested that oxidative stress
and inflammation leads to weak immunologic response
and incomplete virus eradication [109]. In addition, virus
residuals and antigen remnants cause the ongoing inflammatory response and a vicious cycle leading to a chronic
phase known as long COVID [109]. Meanwhile, the persistence of viremia and insufficient antibody generation [139],
as well as, psychological factors like post-traumatic stress
disorder (PTSD) may contribute to the development of the
long COVID [42, 58]. The reason that some individuals are
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more prone to develop long COVID possibly lies in their
genetic profile primarily related to the immune system, such
as human leukocyte antigen (HLA). Future whole genomic
studies may shed more light on this [109].
It has been shown that RNA of SARS-COV-2 may remain
in the central nervous system after the acute phase and may
result in the neuronal loss [140]. The considerable systemic
inflammation in COVID-19, causes generalized endothelitis
and disruption of the blood–brain barrier (BBB) [141, 142].
Moreover, it is known that systemic hyper-inflammation is
a leading cause of neurodegeneration and cognitive decline
[143, 144]. The latter requires longitudinal follow-up and
studies on the pathogenesis and preventive measures, considering the already significant burden of neurodegenerative ailments such as Alzheimer’s and Parkinson’s disease,
to prevent a delayed pandemic of new neurodegenerative
conditions [10, 137].
It is thought that the direct invasion of the virus is responsible for persistent neuropsychiatric features of SARSCOV-2 [145]. Another suggested mechanism for the persistent syndrome is dysregulated immunologic response and
virus-induced cytokine storm. Moreover, the production of
pro-inflammatory cytokines such as IL-7 and IFNγ (interferon-gamma) can result in post-stroke depression, which is
highly similar to pathobiology of SARS-COV-2 [93]. The
COVID-19 patients have a higher level of NLRP3 inflammasome activation that in combination with interleukin-18 and
interleukin-1β have been shown to adversely impact cerebral
function [22]. Also, NLRP3 inflammasome-mediated systemic inflammation can lead to pathological accumulation
of the peptides/proteins such as fibrillar amyloid-β resulting
in the induction and aggravation of neurodegenerative illnesses such as Alzheimer’s disease [146, 147]. It has been
suggested that SARS-COV-2 infection may impair cognitive
function that would lead to brain fog via selective targeting
of the mitochondria of the neurons [104].
Dani et al., described long COVID symptoms, such as
tachycardia, palpitation, orthostatic intolerance, breathlessness, and chest pain as the consequences of autonomic
nervous system instability caused by deconditioning, hypovolemia or immune- or virus-mediated autonomic nervous
system destruction [110]. In a case report of a COVID-19
patient with anti-microbial resistant Pseudomonas Aeruginosa infection, it was documented that 6 weeks after clearing of the viral infection, a significant number of activated
T-cells and T-cells-specific for unrelated antigens were present, suggesting "a significant amount of by stander activation" which might contribute to recurring anti-bacterialresistant infections [148]. A study measuring 96 immune
response-associated proteins showed that even 40 days postCOVID-19 viral infection high levels of biomarkers related
to innate anti-inflammatory and stress response were present
[31].
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The risk factors for developing long COVID
Currently, the healthcare systems of all countries are overwhelmed with providing care for acutely ill COVID-19
patients. Soon, the health care systems will also be overwhelmed with providing long-term care for the survivors of
the acute phase of the illness who are suffering from postacute-phase signs and symptoms, i.e., long COVID. That
made it of paramount importance for the authors to search
for the existing literature on the risk factors for developing
long COVID after surviving the acute phase. Having reliable
criteria to identify such vulnerable individuals would help
the healthcare authorities to prepare for early screening and
diagnosis, and providing proper facilities to care for their
special needs.
In a prospective cohort study of confirmed COVID-19
infected adults, anosmia-dysgeusia was associated with
younger age (< 65 years old), and in cases with severe pneumonia only opacities of lung surface on X-rays > 50% and
higher heart rate at admission were independent predictors
of Long COVID symptoms [50]. Estimated glomerular filtrate (eGFR) ≤ 60 mL/min/m2 and male sex were predictors
of lingering abnormalities on spirometry. Moreover, a higher
imaging score during the acute phase of illness was associated with the persistence of radiologic lung involvement, as
expected [34]. Another prospective cohort study showed that
the duration of oxygen supplementation in the acute phase of
the disease was strongly associated with predicted DLCO %
and total CT scores 12 weeks after symptom onset. Also, a
significant association was found between dyspnea severity
score on 12-week follow-up and predicted DLCO% [67].
Moreover, in a report of 52 cases of COVID pneumonia with
at least 2 chest CT scans of around 3 months apart, a higher
initial CT severity score, ICU admission, longer hospitalization, underlying medical conditions, higher initial WBC
count, and development of leukocytosis during hospitalization were predictors of persistent pulmonary abnormalities
on the second CT scan [23].
Long COVID patients are claimed to be susceptible to
post-viral conditions similar to chronic fatigue syndrome
and myalgic encephalomyelitis [83]. It was also reported
that those with more than 5 symptoms in the first week of
the acute illness were 4 times more susceptible to develop
Long COVID; fatigue, headache, shortness of breath, hoarse
voice, and myalgia were the most predictive symptoms; and
the illness was more prevalent among women, older people,
and those with obesity [136]. In another study, nearly twothirds of adults with non-critical COVID-19 had complaints,
including anosmia, dyspnea, and asthenia, up to 2 months
following symptom onset. These prolonged symptoms
were associated with age 40–60 years, hospital admission
at symptom initiation, severe COVID-19, and dyspnea or
abnormal chest auscultation [48].
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The long-term effects of SARS-CoV-2-associated myocarditis are not known, however, based on the experience
with other viral myocarditis, it is anticipated that those
with a moderate to severe decrease in left ventricular
ejection fraction, almost half would recover in the next
6–12 months, 25% would develop chronic systolic dysfunction, and 25% would require advanced therapies such
as heart transplantation [92]. In addition, as post-viral
myocarditis and other post-viral cardiac complications
can result in a variety of cardiac sequela ranging from
atrial and ventricular arrhythmias to sudden cardiac death,
cardiac monitoring is recommended in such COVID-19
patients for 2–6 months post-recovery [120].
When it comes to long-term mental health problems,
there are multifold risk factors. In regard to PTSD and
chronic psychological distress after the acute phase of
COVID-19, the greater exposure to the illness was associated with a higher incidence of subsequent PTSD. Loss
of a loved one, hospitalization, containment measures such
as isolation and quarantine, being in low-income regions,
financial stressors, having disabilities, female gender, and
older age were the most common mental health risk factors reported by preliminary studies [125]. Another study
revealed that previous psychiatric diagnoses and higher
systemic immune-inflammatory index are associated
with higher post-COVID psychiatric problems. Systemic
immune-inflammatory index (SII) is an objective marker
of the balance between host systemic inflammation and
immune response status considering together peripheral
neutrophil, platelet, and lymphocyte counts. In this study,
the authors explained that hospitalization duration was
inversely correlated with mental health consequences
because less in center healthcare support would increase
self-isolation and loneliness [21]. It has also been reported
that young people, women, and those with responsibilities
and concern for others are more prone to develop posttraumatic symptomatology (PTS) following COVID-19
exposure, and hence, they deserve more attention [58].
Defining the factors that predict the development of
Long COVID require more cohort and longitudinal studies. Since it is anticipated that there will be an enormous
number of long COVID patients in the near future, identifying such predictors could help the Long COVID-specified clinics to prioritize the most vulnerable people and
provide care to those in need.
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Signs and symptoms
Multisystem studies and those related to general
signs and symptoms
The persistent symptoms have been frequently reported.
Huang et al., studied 1733 patients (nearly half men,
median age of 57) in a clinical cohort follow-up in Wuhan,
China. With a median follow-up of 186 days, 76% of the
patients reported at least one persistent symptom, especially in women. The most reported symptoms were muscle weakness and fatigue (63%), followed by sleep difficulty (26%), and anxiety/depression (23%). More than
half of them still had abnormalities in their chest computed
tomography (CT) scan, that was independently associated with their pulmonary involvement during their acute
illness. Also, of 86 patients who had experienced critical acute respiratory symptoms requiring oxygen mask/
cannula and/or invasive/non-invasive mechanical ventilation during their hospital stay, 48 (56%) had impaired
pulmonary diffusion tests in follow up (odds ratio of 4.6,
range of 1.85–11.48). Besides, 13% of those with intact
kidney function at the time of admission showed abnormal
estimated glomerular filtration rate (eGFR) of < 90 mL/
min/1.73 m2 in follow-up. Moreover, among 94 patients
with antibody testing, the seropositivity of neutralizing
antibodies was significantly lower in follow-up (58.5%
with a median titer of 10) comparing to the acute phase
(96.2% with the median titer of 19) [149].
In a prospective cohort study of 183 patients (mean age
57 years, 61.5% male), the persistence of symptoms at
35 days after hospitalization were: fatigue in 55%, dyspnea
in 45%, and muscle pain in 51%, associated with a lower
rating of physical health, mental health, quality of life, and
active social role [55].
In a longitudinal study of 180 non-hospitalized RTPCR proven COVID-19 patients, 53% of patients reported
persistence of at least 1 symptom, and 33% reported 1
or 2 symptoms after a mean of 125 days from the onset
of disease. The most prevalent persistent symptoms were
fatigue, loss of smell and taste, and joint pain [51].
An app-based study about COVID-19 reported that
while most of the patients fully recovered within 2 weeks,
1 in 10 patients still reported symptoms for 3 or more
weeks. Their research showed that some people experienced fatigue, headache, cough, anosmia, sore throat,
delirium, and chest pain as long-lasting symptoms [89].
The Public Health England Guidance implied that 1 in
10 mild cases who have not been admitted to the hospital
had symptoms lasting for 4 weeks [133]. A cross-sectional
study by Mandal et al., reported that the prevalence of
persisting symptoms after a median follow-up of 54 days
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following hospitalization were: breathlessness (53%),
cough (34%), fatigue (69%), and depressive symptoms
(14.6%) [64].
Van den Borst et al., studied 124 patients (mean age
59 ± 14 years, 60% male) 3 months after recovery from
acute COVID-19; 27 patients with mild, 51 with moderate, 26 with severe, and 20 with the critical disease. They
found that a substantial number of patients reported problems across some domains of Nijmegen Clinical Screening
Instrument (NCSI), including impairment in general quality
of life (72%), fatigue (69%), and functional impairments in
daily life (64%) [25].
Arnold et al., conducted a prospective cohort study with
110 COVID-19 survivors (median age of 60 years) who were
followed with a median of 83 days after hospital admission
and 90 days following the onset of COVID-19 symptoms.
They divided the patients into mild (n = 27), moderate
(n = 65), and severe (n = 18) groups. At follow-up, although
most symptoms had been improved, however, 74% of the
patients were still suffering from at least 1 ongoing symptom such as: breathlessness 39%, fatigue 39%, and insomnia
24%. In the mild group, 59% of patients reported ongoing
symptoms, whereas the rates of ongoing symptoms for the
moderate and severe groups were 75% and 89%, respectively
[65].
Townsmen et al., studied 128 post-acute COVID-19
patients (mean age ± SD, 49.5 ± 15 years) at a median follow-up of 72 days after initial COVID-19 symptoms. More
than half of the participants (52.3%) reported persistent
fatigue regardless of the severity of their acute phase. They
also found no association between post-acute COVID-19
fatigue and routine laboratory markers of inflammation and
cell turnover (leukocyte, neutrophil or lymphocyte counts,
neutrophil-to-lymphocyte ratio, lactate dehydrogenase,
C-reactive protein) or pro-inflammatory molecules (IL-6 or
sCD25) [33].
In a longitudinal study of 538 COVID-19 survivors
(54.5% female; median age, 52.0 years), Xiong et al., found
that after a median follow up of 97 days following discharge
from the hospital, almost half of the patients (49.6%) had
one or more of these symptoms: fatigue (28.3%), excessive
sweating (23.6%), arthralgia-most commonly in the knee
joint (7.6%), myalgia (4.5%), chills (4.6%), limb edema
(2.6%), and dizziness (2.6%) [24].
Liang et al., studied 76 COVID-19 survivors (72%
female; median age, 41.3 years) for 3 months after discharge from the hospital. During the 3-month follow-up,
62% of patients complained of chest tightness and palpitation with physical activity. Other symptoms were fatigue
(60%), cough (60%), increased sputum production (43%),
diarrhea (26%), and fever (20%). Interestingly, some of
the laboratory values during the acute phase of illness correlated with post-COVID-19 symptoms. Serum troponin-I
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level during the acute illness had a strong correlation with
fatigue at follow-up (correlation coefficient 0.78, P-value
0.008). Also, lymphocyte count during acute illness had a
negative correlation with chest tightness and palpitations
with activity at 3 months follow up (correlation coefficient − 0.29, P-value 0.03) and (correlation coefficient
− 0.36, P-value 0.004), respectively. AST and ALT levels
in the acute phase were positively correlated with fever at
follow-up (correlation coefficient 0.29, P-value 0.02) and
(correlation coefficient 0.26, P-value 0.04), respectively.
Moreover, AST level and CD4 cell count in acute illness
positively correlated with diarrhea in the follow-up period
(correlation coefficient 0.26, P-value 0.047) and (correlation coefficient 0.29, P-value 0.04), respectively [62].
A study of 143 patients (37% females, mean
age ± SD of 56.5 ± 14.6 years) with a mean follow up of
60.3 ± 13.6 days after onset of the first symptoms demonstrated that a high proportion of individuals still complained of fatigue (53.1%), dyspnea (43.4%), joint pain
(27.3%), and chest pain (21.7%). At follow-up, only 12.6%
of the patients were completely symptom free, while 32%
had 1 or 2, and 55% had 3 or more symptoms, and 44.1%
experienced worsened quality of life [74].
Halpin et al., surveyed 100 COVID-19 survivors (32
ICU patients, 68 ward patients) with a mean follow-up
duration of 48 ± 10.3 days. They found that dysphagia,
laryngeal sensitivity, and voice change were more prominent in ICU patients (12.5%, 25%, and 25%, respectively)
than ward patients (5.9%, 11.8%, and 17.6%, respectively)
[35].
Goërtz et al., studied 2113 COVID-19 survivors in a
web-based search in the Netherlands and Belgium [56]. The
median ± SD of the persistent symptoms was 79 ± 17 days
after the beginning of the signs/symptoms. Of the patients
surveyed 112 had been hospitalized, and 2001 had been outpatients. Fatigue and dyspnea were the most common complaints of the patients at the onset of illness and at followup. Fatigue that had been present in 95% of the patients at
disease presentation, was still present in 87% at follow-up.
Similarly, breathlessness that had been present in 90% of
the patients at the onset of the disease was still present in
71% at follow-up.
Carvalho-Schneider et al., studied 150 patients in Tours
University hospital with a follow-up of 30 and 60 days [48].
Two-thirds of the patients had symptoms in their one and
two-month follow-ups (68% vs. 66%, respectively). The
most-reported signs/symptoms in the day 30 and 60 were
anosmia/ageusia (28% vs. 23%), dyspnea (36.7% vs. 30%),
and asthenia (49.5% vs. 40%), respectively. Their study
concluded that persistent symptoms at 2 months of disease
onset are associated with age (40–60 years-old), abnormal
pulmonary sound at the initial examination, and admission
to hospital [80].
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Respiratory
Multiple studies have looked at long-term effects of COVID19 on the respiratory system. In a retrospective study of 57
adult patients (17 severe and 40 non-severe cases during
their admission), serial lung function tests, imaging studies and exercise capacity were examined 1 month following the discharge [150]. In this follow-up on their convalescent phase, 31 (54%) showed the abnormality in their chest
CT scans. They evaluated the following values: diffusing
capacity for carbon monoxide (DLCO), maximal inspiratory
pressure (PI max), maximal expiratory pressure (PE max),
total lung capacity (TLC), forced expiration volume during
the first second (FEV1), forced vital capacity (FVC), and
FEV1/FVC ratio. With regards to pulmonary function tests,
30 (53%), 25 (44%), 7 (12%), 6 (10.5%), and 5 (9%) patients
had lower values than 80% of predicted in DLCO, TLC,
FVC, and FEV1, respectively. More than half of the participants had PI max and PE max less than 80% of predicted
values, suggesting decreased respiratory muscles strength.
Severe cases had more impaired tests in their follow-up
tests. For instance, they showed significant impairment of
the DLCO (76% vs. 42.5%, P-value 0.019) and a considerably lower TLC [150].
Zhao et al., followed 55 COVID-19 survivors 3 months
after their discharge using HRCT of the thorax, pulmonary
test, and IgG antibody for SARS-COV-2. Thirty-five participants (63%) still complained of the persisted symptoms
[75]. CT abnormalities were still detectable in 39 of 55
(71%) participants. These included almost resolved ground
grass opacities, interstitial thickening and crazy paving pattern with few showing evidence of fibrosis. A quarter of
them had impaired respiratory function tests. Besides, 47
of 55 (85%) patients had positive IgG for SARS-COV-2,
in which females showed a more robust generation of the
antibody as compared to males in the rehabilitation phase.
Moreover, they suggested that on-admission D-dimer levels
may help predict impaired respiratory test in the follow-up
(OR 1.066, 95% CI 1.006–1.129, P-value 0.03). In addition,
they highlighted the correlation between blood urea nitrogen level with the presence of lung abnormalities (OR 7.15,
CI 1.038–49.126, P-value 0.46) [27]. In another prospective cohort study, 277 patients were followed 77 days after
the disease onset. Among them, 141 (51%) were detected
to have at least one clinical symptom. Spirometry abnormalities were detectable in 9.3%, and chest radiology findings were noted in 19%; however, the signs/symptoms and
changes were reported mostly as “mild”. In this study, no
independent risk factor and baseline clinical feature was
notable as a predictor for long COVID [34].
In another retrospective cohort study, Tabatabaei et al.,
investigated chest CT findings of 52 COVID-19 survivors
with a 3-month interval between the initial and follow-up
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CTs. Thirty (57.7%) patients had complete resolution of
pulmonary findings, whereas 22 (42.3%) had the residual
disease, including ground-glass opacities (54.5%), mixed
ground-glass and subpleural parenchymal bands (31.8%),
and pure parenchymal bands (13.7%) on follow-up CT.
Patients with the residual disease had higher CT severity
score on the initial exam (P-value 0.036), longer duration
of hospitalization, higher rates of ICU admission, more
underlying medical conditions, higher initial WBC count,
and higher rates of leukocytosis occurrence during hospitalization (all P-values < 0.05) [23].
Guler et al., evaluated pulmonary function and radiological features of COVID-19 survivors 4 months after mild/
moderate or severe/critical as defined by the WHO severity classification [37]. After adjustment for potential confounding factors, they found that people with severe/critical
COVID-19 had a 20.9% lower predicted DLCO than mild/
moderate COVID-19 patients (P-value 0.01). They demonstrated predicted DLCO as the most potent independent
factor associated with previous severe/critical COVID-19
after including age, sex, BMI, 6-MWT, and minimal SpO2
at exercise in the multivariable model (adjusted OR per
10%-predicted 0.59, 95% CI 0.37–0.87, P-value 0.01). In
terms of radiological evaluation, they found mosaic hypoattenuation on follow-up chest CT to be significantly associated with previous severe/critical COVID-19 after adjustment for age and gender (adjusted OR 11.7, 95% CI 1.7–239,
P-value 0.03) [37].
In a retrospective study of 51 patients with “common
COVID-19”, defined by them as fever with some respiratory-infection symptoms and pneumonia on radiographic
images [41], patients had been followed at 2 weeks and
4 weeks after discharge. In the second follow-up, as compared with the first, the cases with focal ground-glass opacity, multiple ground-glass opacities, consolidation, interlobar
septal thickening, subpleural lines, and irregular lines were
reduced from 17.7 to 9.8%, 80.4 to 23.5%, 49.0 to 2.0%,
80.4 to 35.3%, 29.4 to 7.8%, and 41.2 to 15.7%, respectively. Moreover, lung lesions were fully resolved in 25.5%
of patients on the first follow-up, and in 64.7% of patients
by the 4-week-follow-up [41].
In a meta-analysis of the respiratory function of 380
patients in 6 studies assessed at least 1 month after the onset
of symptoms, altered diffusion capacity, restrictive pattern,
and obstructive pattern were observed in 39%, 15%, and 7%
of the patients, respectively [127].
Truffaut et al., evaluated 22 COVID-19 associated ARDS
survivors 3 months after ICU discharge. In their study, PFT
remained abnormal in 55% of patients with a restrictive pattern ± altered DLCO. Fibrosis was the most abundant finding
of 3-month follow-up chest CT. Low TLC was associated
with the need for mechanical ventilation (P-value 0.044).
The initial number of the affected segments on chest CT
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correlated with DLCO impairment, low FEV1, and the
number of affected segments on 3-month follow-up CT
(P-value < 0.0001, < 0.0001, and 0.01, respectively). Glucocorticoid administration was associated with better outcomes
in the aforementioned parameters (P-value 0.02, 0.008, and
0.04, respectively). The presence of obstructive sleep apnea
was the only predictor of fibrosis on the three-month chest
CT scan among demographic and medical data [75].
Shah et al., conducted a prospective cohort study in which
they investigated PFT, 6MWT, and HRCT of the chest of 60
previously hospitalized patients with a mean age of 67 years
(IQR 54–74 years), and a mean interval of 11.7 weeks after
the onset of symptoms. Regarding pulmonary function,
58% of patients had at least one abnormal variable in PFT.
Abnormal DLCO was seen in 52% of patients, with 45%
of them also having an abnormal total lung capacity indicating a concurrent restrictive ventilatory deficit. Airflow
obstruction, which was defined as FEV1/FVC < 0.70, was
observed in 11% of patients. By the end of a 6MWT, 4 (7%)
patients had SpO2 < 88%. In terms of radiologic findings,
83% of patients had ground-glass abnormality, whereas 65%
had reticulation, and 12% had neither imaging abnormality.
More than half (55%) of patients had > 10% of lung volume
affected by either ground glass or reticular appearance. The
aforesaid patients accounted for most patients who warranted mechanical ventilation (67%) and oxygen supplement (65%). They also observed that the number of days on
oxygen supplementation during the disease’s acute phase
correlated with both DLCO%-predicted and total CT score.
Similarly, there was a strong association between dyspnea
severity and predicted DLCO [67].
Xiong et al., studied symptoms in 538 COVID-19 survivors (54.5% female) with a median age of 52.0 years (IQR
41.0–62.0 after a median time of 97.0 (95.0–102.0) days
from discharge to first follow-up. They found that 39% of
patients had one or more respiratory symptoms, including
post-activity polypnea (21.4%), which was caused by just
mild activity, chest distress (14.1%), chest pain (12.3%),
cough (7.1%), nonmotor polypnea (4.7%), throat pain
(3.2%), and excessive sputum (3%). Except for excessive
sputum, the prevalence of all symptoms was significantly
higher in the survival group as compared with the comparison group (all P-values < 0.05) [24].
Bellan et al., evaluated PFT in 224 hospitalized COVID19 patients (59.7% male) with a median age of 61 years
(IQR 50–71 years) 3–4 months after discharge. Median
FEV1 was 101% (IQR 91.5–112%) of expected, and median
FVC was 98.5% (IQR 90–109%) of expected. Five patients
were unable to complete the assessment of DLCO; therefore, it was measured in 219 patients. Median DLCO was
79% (IQR 69–89) of expected. 51.6% of patients had DLCO
less than 80% of expected, for which the risk factors were
female sex (OR 4.33, 95% CI 2.25–8.33; P-value < 0.001),
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CKD (OR 10.12, 95% CI 2.00–51.05; P-value 0.005), and
the modality of oxygen delivery during hospital stay (OR
1.68, 95% CI 1.08–2.61; P-value 0.02). DLCO < 60% of
expected was observed in 15.5% of patients and the risk factors were female sex (OR 2.70, 95% CI 1.11–6.55; P-value
0.03), COPD (OR 5.52, 95% CI 1.32–23.08; P-value 0.02),
and ICU admission during hospital stay (OR 5.76, 95% CI
1.37–24.25; P-value 0.02) [68].
In a study of 124 patients (27 patients with mild, 51 with
moderate, 26 with severe, and 20 with the critical disease)
with a mean age of 59 ± 14 years (60% male) 3 months after
recovery from acute COVID-19, Borst et al., reported that
patients referred from general practitioners with the mild
persistent disease had a higher score on modified Medical Research Council (mMRC) dyspnea scale in comparison to moderate to critical patients. Mean resting oxygen
saturation was 96 ± 1%, and mean spirometric indices
were normal among all study groups. Moderate to critical
patients had significantly lower mean DLCO as compared
with mild patients who had normal mean DLCO. Also,
critical patients had the lowest mean TLC and residual volume (RV). In regards to radiologic findings, 93% of mild
referred patients had normal chest X-rays while only 7%
had signs of mild bronchial disease. Ground glass opacities
were decreased on follow-up chest CT in 99% of discharged
patients and was unchanged in 1%. Nine percent of patients
had no abnormalities on chest CT scan. In contrast, residual
ground-glass opacity, bronchi(ol)ectasis, lines or bands,
and radiological signs of fibrosis were still present in 86%,
60%, 64%, and 26% of patients, respectively. The presence
and number of residual CT scan abnormalities were associated with lower DLCO. Moreover, the presence of signs of
fibrosis was in association with older age (P = 0.004), lower
TLC (P = 0.03), and more frequent desaturation during the
6MWT (P = 0.03) [25].
After studying 76 COVID-19 survivors (72% female)
with a median age of 41.3 years (IQR 24–76 years) 3 months
after discharge from the hospital, Liang et al., found that
lung HRCT had returned to normal in 82% of patients;
while 42% of the survivors still had mild pulmonary function abnormalities 3 months following the discharge [62].

Cardiovascular
The long-lasting effects of COVID-19 frequently involve the
cardiovascular system. In one longitudinal study, 60% of
patients still had myocardial inflammation 71 days after their
initial diagnosis, a finding that was possibly contributing
to concomitant chest pain, dyspnea, and fatigue. Moreover,
an astounding 78% of study subjects had abnormal cardiac
MRI findings [54]. Sollini and colleagues used positron
emission tomography/computed tomography (PET/CT) to
demonstrate that SARS-COV-2 infection could also induce
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vasculitis, which again was correlated with patients’ prolonged symptoms [77]. In a study of 538 COVID-19 survivors (median age of 52.0 years, 54.5% female) followed
for a median time of 97 days (range 95–102 days) from discharge to first follow-up, Xiong et al., found that 13% of
patients complained of persistent cardiovascular symptoms
[24]. Of these patients, 75% experienced increased resting
heart rate which had lingered since index hospitalization and
4.8% suffered from palpitations. High resting heart rate was
significantly more prevalent in the survival group than the
comparison group (P-value < 0.05) [24]. More unusual heart
rate syndromes have also been reported. In a case report of
a 26-year-old female who recovered from the acute phase
of COVID-19, postural tachycardia syndrome (POTS) was
reported early in her disease process which persisted for the
entire 5.5 months of follow-up [112].
Depending on the age-group involved, there is evidence
that COVID-19 infection can predominantly promote features of subclinical myocarditis. This is best illustrated in a
cardiovascular magnetic resonance (MRI) study of 26 competitive college athletes [151]. None of the 26 participants
required hospitalization, and most (73%) were asymptomatic. Twelve athletes (27%; including 7 female athletes)
experienced mild symptoms such as sore throat, myalgia,
dyspnea, and fever 12–53 days following their quarantine
period. Subsequent cardiac MRI revealed ongoing myocarditis or prior evidence of myocardial injury in 12 subjects
(46%) despite largely normal ejection fraction [151]. In a
similar study, Malek et al. evaluated the cardiac MRI of 26
consecutive elite athletes with a median age of 24 years [39].
Participants were mainly asymptomatic or experiencing a
mild course of the disease (77%). Although there was no
evidence of pathologic electrocardiogram abnormalities or
elevated troponin levels, cardiac MRI was abnormal in 5 of
26 (19%) athletes, including 4 with features of isolated myocardial edema and 1 manifesting non-ischemic late gadolinium enhancement with pleural and pericardial effusion [39].
With more ongoing longitudinal studies of the cardiovascular effects of COVID-19 reporting evidence for myocardial
damage, there is increased concern for late-onset myocardial dysfunction and heart failure in the general population.
As seen with other organ systems, this will manifest more
overtly in the elderly population with co-morbidities [152].
However, evidence for subclinical myocarditis in young
athletes raises concerns for undetected arrhythmic episodes
and the potential for sudden cardiac death in subjects with
overtly preserved ventricular function [153].

Musculoskeletal
A cross-sectional study demonstrated a high prevalence
of skeletal muscle weakness and poor physical performance in post-acute COVID-19 patients who had no prior
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musculoskeletal problems. For instance, weakness of quadriceps and biceps muscles was found in 86% and 73% of the
post-acute COVID-19 patients, respectively [53]. Other
studies have shown that most of the post-acute COVID-19
survivors suffered from impairment of functional and muscular performance and dyspnea resulting in severe disability
and poor perceived health [45, 72].

Cutaneous
There are a number of reports on the cutaneous manifestations of COVID-19 [154–156]. The International League
of Dermatological Societies and the American Academy
of Dermatology recently released the first report of their
international registry of skin manifestation of COVID-19 in
Lancet Infectious Disease [90]. The healthcare providers of
41 countries had shared their observation of cutaneous manifestations of suspected and confirmed COVID-19 cases in
that registry. In their report, among the laboratory-confirmed
patients, urticarial eruptions lasted for a median of 4 days
(maximum of 28 days), papulosquamous eruptions lasted for
a median of 20 days (maximum of 70 days), pernio (COVID
toe) lasted for a median of 12 days (maximum of 133 days).
Of 103 patients with pernio, 7 (6.8%) patients experienced
pernio for longer than 2 months [70]. Interestingly, pernio
is attributed to inflammation in acral small vessels, highlighting the pathogenic role of chronic inflammation and
vasculitis [157]. In another study of 538 COVID-19 survivors (54.5% female, median age of 52.0 years) at a median
follow-up time of 97 days after hospital discharge alopecia
was reported in 28.6% of the patients [24]. Interestingly,
alopecia occurred significantly more in females than males
(P-value < 0.01). Moreover, among 154 COVID survivors
with alopecia, in only 42 (27%) patients it had started during
hospitalization, and in the remaining 112 (73%) patients it
had started after discharge from the hospital [24].

Neurologic
Headache, vertigo, “Brain fog”, loss of smell and taste sensations (anosmia and ageusia), collectively referred to as
"Neuro-COVID" or “Post-COVID-19 Neurological Syndrome” are among the most reported complications of long
COVID in the central nervous system (CNS) [109, 158].
As an example, loss of smell (anosmia) may last beyond
2 months in 10% of the inflicted population [46]. It is suggested that viremia and invasion of the brain and olfactory
bulb leads to anosmia [152]. Imaging studies of the olfactory
bulb have revealed that olfactory cleft and olfactory bulb
abnormalities are present in patients with persistent COVID19 anosmia, and that a majority of such patients have olfactory bulb atrophy and degeneration [32, 73]. One-third of the
COVID-19 survivors had cognitive and/or motor impairment
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at their discharge from the hospital [159]. A case report also
raised the possibility of Guillain-Barré syndrome being a
rare late neurological complication of long COVID-19 syndrome [116]. In an imaging analysis using positron emission tomography (PET Scan) several regions of the brain
showed hypometabolism, such as orbital gyrus, olfactory
gyrus, temporal lobe, amygdala, hippocampus, thalamus,
pons/medulla brain stem and cerebellum with 100% accuracy in distinguishing symptomatic long COVID-19 patients
from matched normal controls. Such brain involvements
could explain the neurologic symptoms, such as hyposmia/
anosmia, memory/cognitive impairment, pain and insomnia. The hypometabolism seemed to be associated with the
consumption of ACEI medications, reflective of the possible
role of ACE receptors; meanwhile, this study suggested that
using nasal decongestant sprays might be protective in this
context [20].

Mental health
One of the great concerns of long COVID is its mental health
consequences, such as major mood swings, depression, the
feeling of loneliness and isolation, high levels of stress and
anxiety, and sleep–wake disorders [160]. The survivors are
also at risk of the community-wide psychological toll of
the pandemic with a higher chance of chronic fatigue syndrome, depression, post-traumatic stress disorder (PTSD),
substance/drug abuse and anxiety [152]. Decreased healthrelated quality of life was implicitly reported in a case–control study as a significant consequence of long COVID [38].
In a qualitative study of the persistent symptoms after
COVID, multiple diverse and often relapsing–remitting
symptoms were reported. The patients felt a heavy sense
of stigma, not being taken seriously and achieving a diagnosis, inability to access specialists’ services, inconsistent
criteria for investigating or referring the patients. Moreover,
the researchers found a considerable degree of emotional
feelings, such as anger, frustration, fear, and hopelessness
among these patients [57]. Another qualitative study implied
the following themes: the hard and heavy work of enduring
and managing symptoms and accessing appropriate care,
living with uncertainty, helplessness and fear, particularly
over whether or not recovery is possible. The authors also
mentioned the importance of finding the ’right’ general
physician/family practitioner to present an adequate level
of understanding, empathy, and support [47]. Moreover,
another study estimated that long COVID might cause
unexpected cognitive dysfunction, equivalent to a 10-year
decrease in global cognitive performance between the ages
of 20 and 70 years [136].
Furthermore, Mazza, et al., studied a cohort of 402 adult
survivors of COVID-19 who were screened for psychiatric symptoms of post-traumatic stress disorder (PTSD),
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depression, obsessive–compulsive disorder (OCD), anxiety and insomnia at 1 month follow up after hospital treatment. They found that 56% of the post-COVID patients had
ongoing symptoms of at least one, 37% had two, 21% had
three, and 10% had four of the aforementioned psychopathological conditions. The authors also found that females,
patients with a preexisting psychiatric diagnosis, and those
who were managed at home had an increased score on most
measures. Outpatients suffered from increased anxiety and
sleep disturbances, whereas the duration of hospitalization
had a negative correlation with PTSD disorder, depression,
anxiety, and OCD symptoms. Moreover, higher levels of
depression and sleep disturbances were observed among the
younger patients [21]. Their results were in agreement with
another cohort of 238 COVID-19 survivors studied 4 months
after hospital discharge in whom PTSD symptoms were
reported in 43% (26% had mild, 11% had moderate, and 6%
had severe PTSD symptoms). Moreover, in contrast to the
previous study, male sex was independently associated with
moderate to severe PTSD symptoms [68].
Xiong et al., reported on 538 COVID-19 survivors (54.5%
female, median age of 52.0 years) after a median follow-up
of 97 days from hospital discharge. They found that psychological symptoms were present in 22.7% of patients as
follows: somnipathy in 17.7% (mainly described as difficulty
falling asleep or short and interrupted sleep), and depression
and lack of interest in things in 4.3% [24].

Pediatric long COVID
Long COVID in the pediatric field is a real challenge, which
is poorly defined. Only one published case series considered
the long COVID in 5 inflicted children. The most common
signs/symptoms reported were fatigue, dyspnea, palpitations, and chest pain. However, the symptoms ranged from
headache to skin rashes. This study also mentioned that
the duration of illness was longer in children than in adults
[111].
Predominantly in children and recently found few cases in
adults, the SARS-COV-2 has resulted in a hyperinflammatory state called multisystem inflammatory syndrome (MIS),
which was later divided into MIS in Children (MIS-C) and
MIS in adults (MIS-A). The disease resembled acute rheumatic fever, toxic shock syndrome and Kawasaki disease
that was misdiagnosed in the beginning [161–163]; however, later, it was found to be a post-infectious state of the
SARS-COV-2 primarily following 4–6 weeks after infection. In general, the syndrome may present with a combination of fever, abdominal pain, dermatologic manifestations, diarrhea, nausea, and organ failure [162]. Among the
presentation sign/symptoms, the cardiovascular symptoms
are more prominent: up to 80% of the patients may have
symptomatic myocarditis, 9–24% may present with coronary
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artery abnormalities and valvular regurgitation, pericarditis,
and pericardial effusion [162]. The prognosis and long-term
complications of the MIS are currently unclear. However,
the hyperinflammatory nature of the syndrome may predispose the victims to complications such as, coagulopathy,
aneurysm, and thrombosis [9], which necessitate further
investigations. In the most extensive study of MIS-C cases
across the united states, 570 children were assessed. Threefourth of the cases had serological evidence of SARS-COV-2
infection, and less than half of them had negative PCR test
for SARS-COV-2 [43]. Moreover, CDC has described MIS
in 16 adults (MIS-A); in 11 of them anti-SARS-COV-2 antibody was checked, all had positive serology. Six of the 16
adult patients had negative SARS-COV-2 PCR tests [113].
These findings highly suggest that MIS-C and MIS-A are
post-acute and postinfectious phenomenon. It has been suggested that endothelial injury and activation of Interlukin-1
pathway has an important role in the pathogenesis of MIS-C
and may serve as a common determinant among MIS-C,
acute rheumatic fever, and Kawasaki disease [121].

Thromboembolism
As far as coagulation dilemmas are concerned, there have
been case reports of thrombosis occurring after discharge
from the hospital [114, 117, 118]. In a study of 163 COVID19 patients who had not receive any anticoagulation prophylaxis during their illness, it was shown that 30 days after
discharge from hospital the cumulative incidence of both
arterial and venous thrombosis was 2.5%; the cumulative
incidence of venous thromboembolism alone was 0.6%.
The 30-day cumulative incidence of major hemorrhage was
0.7%, and clinically relevant non-major bleeds were 2.9%
[66]. Consistent with these results, another study reported
2.6% incidence of venous thromboembolism within 42 days
of discharge from the hospital [30]. This should raise our
awareness toward continuing and/or starting thromboprophylaxis after discharge. However, another study of 102
patients with 44 days of follow-up, revealed less than 1%
incidence of venous thromboembolism, thus no need for a
routine prophylaxis regimen [50]. Moreover, a large study
comparing hospital-acquired venous thromboembolism
associated with COVID-19 and all other medical illnesses
in 2019, showed that the incidence was 4.8 and 3.1 per 1000
discharged individuals, which was not significantly different.
In this study, hospital-acquired venous thromboembolism
was defined as occurring in the hospital at least 48 h after
admission, or postoperatively, or occurring up to 90 days
post-discharge [36]. Similarly, a multi-center study showed
that the incidence of venous thromboembolism in COVID19 patients who were followed for 45 days after hospitalization was “relatively low”[29]. Moreover, Eswaran et al.,
reported that among 447 patients who were followed after
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discharge from the hospital, only 2% developed vascular
thromboembolism 30 days after discharge; and they concluded against the routine post-discharge thromboprophylaxis [69]. In light of these controversies, there is an urgent
need for more extensive randomized clinical trials.

Management
General care
Greenhalgh et al., made recommendations for family physicians and general practitioners regarding long haulers [105].
They mentioned that in long haulers, symptoms should not
be underestimated; for example, chest pain should be taken
even more seriously. They have also recommended pulse
oximetry and home-based assessment for all COVID-19
survivors, urging further investigation for those with oxygen saturation < 95%, and additional tests for evaluation
of exertional desaturation for patients with resting oxygen
saturation ≥ 96%. A 3% or more decrease in exertional oxygen saturation requires further cardiorespiratory assessment
[105].
Because of the diversity of the affected populations’
symptoms, a personalized and holistic approach to symptom
management is recommended. Thus, we highlight the need
for continuing medical education (CME) programs on long
COVID, especially for general primary care practitioners.
Training health care workers in managing their stress while
enabling positivity and connectedness for patients is also
critical. Poor mental health consequences are highly associated with social exclusion. Therefore, building hope and
resilience, social connection, and peer supports are essential in managing psychological issues [134]. In a qualitative
study on 43 health professionals, Ladds et al., [26] reported
that the participants repeatedly mentioned the role of social
media in feeling better and diminishing their anxiety/stress
and stigma when communicating with others and with their
colleagues about their symptoms.

Pharmacological options
As hypothesized above, the core mechanism that possibly
leads to chronic symptoms is an ongoing inflammatory state
and oxidative stress. If proven, non-steroid anti-inflammatory drugs (NSAIDs), corticosteroids, and antioxidants such
as CoQ10 could be possible approaches to management
[109, 124].
Considering the nature of multisystem inflammatory syndrome in children (MIS-C), four initial treatment domains,
including supportive care, empirical broad-spectrum antibiotics, anti-inflammatory agents, and anticoagulants are
suggested. Anti-inflammatory management aims to reduce
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tissue inflammation to prevent or slow down the progression
of coronary artery aneurysms [121].
Regarding anti-inflammatory agents, high dose IVIG and
aspirin are advised as in Kawasaki disease [164]. However,
there has been a debate over the administration of steroids
in MIS-C. More recent studies suggest the use of corticosteroids based on each patient’s condition guided by a multidisciplinary team [121]. Agents that target inflammatory
molecules such as IL-1 [165], IL-6 [166], and TNF-α [167]
are also suggested for the management of MIS-C.
While these medications might be protective on some
occasions, these drugs’ pros and cons should be weighed
before prescribing due to the possible adverse effects.
Metastasio et al., in their case study, reported using Kratum (Mitragyna speciosa) in their patient resulted in early
recovery from the acute COVID-19 syndromes, including
body pain, fatigue, and malaise, which are challenging
for patients/physicians to deal with [168]. The therapeutic
benefits of the plant are possibly related to the fact that it
is a rich source of mitragynine, and the related metabolite
7-hydroxymitragynine[169]. Further studies may reveal the
herbals’ benefit in long COVID haulers, especially for those
with contraindications for NSAIDs. The harms and benefits
of over-the-counter vitamins and supplements are unknown
[134]. Although this is an early systematic review in the
field, our qualitative assessment of the literature does not
support prophylactic use of the anticoagulants for COVID19 survivors; this requires multinational large-scale cohorts
RCTs.

Role of physical and mental rehabilitation
Post-acute care is usually defined as the care provided following release from the hospital; however, here we extend
this concept further to those surviving from an acute phase
COVID-19, whether or not the patient had been admitted
to a hospital. We recommend that the local public health
authorities should develop adaptive post-acute COVID-19
care centers that specifically work on the palliative care of
COVID-19 long haulers. Importantly, the vulnerable populations such as those in nursing homes, residential care centers,
refugees, and asylum seekers should not be neglected [107].
As long COVID has a multisystem involvement, it has been
suggested that a broad range of rehabilitation disciplines
would be beneficial [128]. Cough and breathlessness are
common. If there is no sign of superinfection or low oxygen
saturation, breathing control exercise could help. The role
of graded exercise in fatigue management is still a source
of debate, and in long COVID patients it should be considered cautiously [134]. Myalgia Encephalomyelitis (ME)
Association on post-viral fatigue syndrome (PVFS) highlighted the role of a multidisciplinary approach in managing
chronic fatigue; it included resting, activity management,
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mental well-being, nutrition, and adequate sleep [78]. Also,
based on the experience of post-infectious fatigue syndrome
induced by Q-fever, it was generally thought the cognitivebehavioral therapy (CBT) could be beneficial in the management of post-infectious fatigue syndrome [170]; however, a
recent study by Vink et al., reanalyzed the results of “Qure
study” and showed that CBT was neither helpful in that
regard nor possibly in the post-infectious fatigue syndrome
of COVID-19 [119].
Another point to consider is early rehabilitation; the current definition of the recovery from COVID-19 is misleading as it mentions 3 weeks or without an episode of fever.
We suggest that full recovery should be considered when
the post-acute symptoms are adequately addressed; in doing
so, Belli et al., in their study showed that the majority of
their study population had a very severe degree of disability
(dependency) at the time of discharge, demonstrated by Barthel index ≤ 60, requiring early rehabilitation [52]. Barthel
Index is used to assess performance in activities of daily
life (ADLs). In a report of the Italian cohort of post-acute
COVID-19 patients, all of the included participants were
grade 4 or 5 on the mMrc dyspnea scale, suggesting dyspnea
during even minimal activities, and only a few of them could
perform the 6-min walk test (6MWT) [45].
For those discharged from the hospital, Sun et al., recommend aerobic exercises, balance training, breathing training,
and resistance strength training (start with low intensity and
gradually raise the duration and intensity) as being beneficial in early recovery [123]. In a case series, Ferraro et al.,
recruited 7 post-acute infectious patients. All of the participants underwent a tailored rehabilitation intervention twice
a day, each time for half an hour, for 6 days a week. In the
beginning, 6 of 7 patients had fatigue, and 1 of them had an
extreme sense of exertion. Following rehabilitation, 5 of 7
were without fatigue, and the remaining 2 had only a light
sense of exertion. Besides, at the beginning of the study,
all 7 patients had a deficient physical performance using
the metrics of 6 MWT and 10 MWT. In this regard, the
authors found a considerable improvement in outcomes of
all patients, especially in 2 cases [71]. Liu et al., did a prospective 6-week respiratory rehabilitation, quasi-experimental study, with 72 post-acute COVID-19 patients discharged
from the hospital (36 with and 36 without respiratory rehabilitation). They found that 6-week respiratory rehabilitation
improved their respiratory function tests, their level of anxiety, and their quality of life in the elderly patients post-acute
phase COVID-19 (all P-values ˂ 0.05) [60].
We would also like to highlight the development of more
relevant functional assessment tools for COVID-19 survivors. For example, in spite of the broad use of 6 MWT in
long COVID-related literature, it has been criticized as it
shows "floor effects" because of respiratory failure and dyspnea in the acute phase, especially for discharged from ICU.
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Concerning this, Rivera-Lillo et al., suggested using 1-min
sit and stand test instead of 6 MWT in the general population
[171]. Also, Curci et al., suggested Chelsea Critical Care
Physical Assessment Tool (CPAx) for those discharged from
the ICU [172].

When to return to usual activities?
The crucial question is: “when can the survivors return to
usual pre-infection activities?”. There is a paucity of evidence concerning this issue; however, we believe that this
decision should also include the patients’ occupation/activity
and should be made on a one-by-one basis. For example,
additional follow-up tests may be warranted in the case of
competitive athletes who wishes to return to the field. A
recent expert consensus recommended that mildly symptomatic athletes, besides 2 weeks of convalescence, should
have a normal electrocardiogram and transthoracic echocardiography prior to returning to competitive sports [173]. In
their review, Mitrani et al., [120] mentioned that there is no
guideline to help physicians deal with the cardiac COVID-19
long haulers in their follow-up to rapidly diagnose complications such as arrhythmias or cardiomyopathies. There is an
absolute need to screen for residual cardiac involvement in
the convalescent phase of acute cardiac injury and for longterm sequelae of “post–COVID-19 cardiac syndrome”. The
issue could become more complicated with a lack of proper
assessment tools; Starekova et al., in a study of the utility of
cardiac MRI as a screening tool among 145 asymptomatic or
mildly symptomatic athletes who survived COVID-19, concluded that cardiac MRI is not useful in the cardiac assessment of the survivors [63].
Salman et al., propose a protocol for returning to the usual
physical activity for the COVID-19 survivors [131]. There
are several concerns about how and when the COVID survivors should start their physical activity/exercise. Some
potential risks, including cardiac, pulmonary, and psychiatric, have to be stratified and considered before advising the
return to physical activity. Besides, the physicians should
consider patients’ pre-illness baseline physical activities
before any recommendation. Those with persistent symptoms or a history of severe COVID-19 or cardiac involvement of COVID (e.g., myocarditis) are recommended to
consult their medical doctor before returning to physical
activities.
Also, Salman et al., recommended waiting at least a week
after being asymptomatic to resume exercise. Moreover, the
first 2 weeks of exercise should be minimal exertion, with
gradual progression. The self-monitoring of the signs/symptoms and mood using a diary is highly recommended in all
steps. For example, suppose patients felt fatigued or unable
to feel recovered one hour or a day after exercise; in that
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case, they should step back to the prior activity level and
seek medical advice when unsure.

Concluding comments and further suggestion
We found many discrepancies and lacunae in the myriad of
papers available on the subject with data based on isolated
cases and lacking the numerical strength for reliable data
analysis. We found only one randomized clinical trial. We
found a significant void of global collaborative studies on
COVID 19 patients, their clinical presentation, management
and long-term effects of the disease. We need a global consensus on the nomenclature of the long COVID 19 syndrome
with a clear definition of the timeline to differentiate between
prolonged symptomatic infection and actual post-recovery
COVID 19 syndrome. Likewise, the diagnostic criteria need
to be clearly established based on the severity of infection.
More research is needed to focus on the pathophysiology of
this complicated ailment. The clinical presentation needs to
be analyzed between the spectrum of age, gender, race and
concurrent comorbidities. Long-term follow-up has to be
established with a clear focus on identifying the risk factors
that predispose certain individuals to more complications
versus others and a timeline for repeat testing or intervention
and rehabilitation.
The unique pattern of morbidity and mortality that spans
across a wide spectrum of demographics mandates that a
more detailed, holistic approach is dedicated to the research
of COVID 19 and its long-term effects.
After about 12 months following the declaration of the
SARS-COV-2 pandemic by the World Health Organization,
mysteries about this new virus, including the extent that the
infection could cause long and persistent symptoms, are still
not clear. There are also debates regarding the definition of
prolonged disease, its diagnosis criteria, and its management. We highlight that the burden of the long COVID is
overgrowing as more individuals become affected by the
disease. Investigations in this field require considerable
funding support and research investment. Also, we strongly
suggest patient tracking via disease registries, similar to cancer registries.
Unfortunately, there is a wide gap in the literature
related to the long-term COVID, which may reflect the
need for long-term multi-national studies with adequate
funding. This would allow for extensive subgroup analyses involving a wide range of ages, ethnicities, occupations, gender, and socioeconomic status. These studies will
bring a more precise definition and symptom categorization for the long COVID. We also highlight the need for
more rigorous research and developing special guidelines
in particular populations such as those with comorbidities
and those with the risk of specific complications, such as
competitive athletes. As stress is considered to play a role
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in the progression of the long COVID, the health care
workers, as front-liners, are possibly more prone to have
higher stress/anxiety and may experience a more symptomatic long COVID, which requires attention and further
research [42, 58].
Moreover, unique guidelines need to be developed for
particular occupations and activities, such as professional
athletes, in whom the long COVID may be associated with
more severe and potentially fatal consequences. We also
highlight the need to support the vulnerable population by
allocating financial and human resources to establish and
reinforce telemedicine and in-person long COVID clinics.
Finally, SARS-COV-2 has not been with us for long enough
time for us to have a realistic estimation of the long-term
picture of the post-infectious state; with the emergence of
new studies, subsequent updated reviews are expected to
appear soon.
To fill the above gaps, we present the following
suggestions:
Definition and management of the evolving nature of
the disease: World Health Organization did well in naming the COVID-19 for standardizing the literature; there
is also a need to develop a timeline for COVID-19, and
appropriate action plans in managing this complex disease.
In that regard, recovery from COVID-19 is far from just
being tested negative or following a limited predetermined
period; a consensus on the definition of full recovery should
be reached. In addition, the diversity of symptoms requires
a more stringent categorization of symptoms; this will help
the treatment and rehabilitation programs.
Long-term patient follow-up and global data-sharing:
more long-term follow-up of the cross-country populations
is recommended. Long-term studies should include all
COVID-19 patients, even those with mild symptoms.
Investing in recovery support, including mental health
and psychosocial support: since many of these patients have
impaired performance in their daily tasks and suffer from
mental health symptoms, launching an in-person or online
portal based on peer groups is crucial.
Building capacity and knowledge base of health care
workers: to deal more efficiently, we highlight the role of
continuing medical education (CME) courses in developing competencies regarding attitudes, skills, and knowledge,
especially for primary care practitioners.
Personalized and more organized clinical management
approach: since individual patients might experience specific
symptoms, the need for personalized holistic management
is notable.
Developing innovative assessment tools for further studies: since this is a new disease that affects all organs, developing newer functional metric tools to address its long-term
impact on the mental and physical health status of the survivors is of paramount importance.
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